Menten Ai

Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability. We partner with top-10 pharma leaders (e.g, Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.